Navigation Links
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
Date:11/8/2007

"_new">http://www.frx.com.

About Milnacipran

Milnacipran is a unique dual-reuptake inhibitor, which preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters known to play an essential role in regulating pain and mood. It has been approved for the treatment of depression in over 32 countries, with real-world commercial experience outside the U.S. spanning more than 10 years and 20 million patient-months. Milnacipran is being developed for fibromyalgia in the United States market jointly by Forest and its licensor, Cypress Biosciences, Inc. Milnacipran was originally developed by and is sold outside of the U.S. by Pierre Fabre Medicament.

About Fibromyalgia

FMS is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue, insomnia and mood symptoms. According to the American College of Rheumatology, FMS is estimated to affect over six million people in the United States. FMS is most often diagnosed in the primary care setting and, in addition, is the second most commonly diagnosed condition in rheumatology clinics in the United States after osteoarthritis. Despite the high prevalence and severity of this syndrome, there are limited treatment options specifically approved for FMS in the United States or elsewhere, and the addressable patient population is not yet well established.

About Cypress

Cypress is committed to being an innovator and leader in providing products for the treatment of patients with Fibromyalgia Syndrome. As part of its business development strategy, the company evaluates a number of Proof of Concept stage opportunities that leverage its repurposing experience and innovative approach to clinical trial design and regulatory strategy, and intend to continue to do this on an ongoing basis. The company continues to evaluate various other potential strategic transactions, including the
'/>"/>

SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014   Plexus Information ... of Anesthesia Information Management Systems (AIMS), announced a ... , a wholly owned subsidiary of Quality Systems, ... systems and connectivity solutions.  Logo ... This partnership extends the ...
(Date:10/1/2014)... -- ResMed (NYSE: RMD ), a pioneer and innovator ... complete sleep apnea solutions specifically for women, is launching a ... good night,s sleep. The Better Sleep For ... is just part of living a busy life. It will ... of health, essential to not only living an active lifestyle ...
(Date:10/1/2014)... 2014 Trovagene, Inc., (NASDAQ:  TROV) a ... Eli Diamond , MD, Assistant Attending Neurologist ... clinical data from an ongoing study demonstrating the ... the determination of oncogene mutational status in cell-free ... were presented to both treating physicians and patients ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... SAN DIEGO, July 9 Arena Pharmaceuticals, ... results from a multiple-ascending,dose Phase 1b clinical ... safety,pharmacokinetics and pharmacodynamics. APD791 is Arena,s internally,discovered ... of arterial,thrombosis and other related conditions., ...
... July 8 After meeting on July 1st ... new diabetes drugs should,undergo trials to rule out ... US endocrinologists agree with this recommendation, according to,AlphaDetail ... market,research and key opinion leader mapping solutions to ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications. 2
(Date:10/2/2014)... October 02, 2014 Social-Engineer, Inc. the ... announced today it will host a complimentary webinar on ... will reveal the final outcome of the annual Social-Engineer ... 22 in Las Vegas and explore how to maximize ... attacks. To register for the webinar go to: ...
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, ... birth control -- especially long-acting implanted devices -- could slash ... average, new findings suggest. In a study of 1,400 ... cut the girls, rates of unplanned pregnancy and abortion. Over ... girls -- versus a rate of 158 per 1,000 among ...
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Medical discovery first step on path to new painkillers 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
... of a landmark study, researchers at Mayo Clinic,s Florida campus ... need to remove colon polyps that are not cancerous or ... to one-half of the polyps removed during colonoscopies end up ... and this increases time, expense and the potential for complications ...
... amo, a destination spa,at Enchantment Resort, for a ... winter solstice on December 21. Activities include a,series ... Program Director R.J. Joseph and special guest, Elder ... from the Blood Reserve,in Standoff, Alberta, Canada,s largest ...
... announcement of planned bequest comes at stem cell symposium, ... one year,ago, retail pioneer A. Alfred Taubman announced a ... a new research institute aimed at,understanding, treating and preventing ... he did it again --,announcing that he will bequeath ...
... Wanted to Know But Was Afraid to Ask!, ... babies born,in the U.S. each year but there,s not ... is a revealing, entertaining and inspirational DVD that,offers invaluable ... gone through the pregnancy and delivery process. It includes,a ...
... LAKE CITY University of Utah researchers have developed a ... to the wall of the heart,s left atrium in patients ... results of the study are published in the Oct. 7, ... of Cardiology . , Atrial fibrillation (AF) is an ...
... ) (OTCBB:WYND), the ideas-to-revenues social media company, ... ( www.muveinc.com ), to create an interactive ... activity-based corporate wellness program. Wyndstorm,s design project ... the use of wellness programs among employees ...
Cached Medicine News:Health News:Mayo Clinic estimates new, tiny, super-sensitive probe could cut colon polyp removal in half 2Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: